PMEF
RXRX icon

Point72 Middle East FZE’s Recursion Pharmaceuticals RXRX Stock Holding History

Point72 Middle East FZE’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,376
Closed -$89.2K – 2009
2023
Q1 		$89.2K Buy
+13,376
New +$106K ﹤0.01% 1154

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Point72 Middle East FZE's RXRX Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Recursion Pharmaceuticals (RXRX) in Q2 2023, closing a stake of 13,376 shares — an estimated $89.2K sold.

Point72 Middle East FZE first reported a position in RXRX in Q1 2023 and held it in 1 quarter. The position peaked at $89.2K in Q1 2023. 158 funds tracked by Wall St. Rank hold RXRX as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Recursion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 13,376 Recursion Pharmaceuticals shares in Q2 2023, an estimated $89.2K.
  • Point72 Middle East FZE first reported a position in Recursion Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Recursion Pharmaceuticals position peaked at $89.2K in Q1 2023.
  • 158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.